Hometown City/Country: Bristol, TN
Undergraduate Degree/Institution: BS/East Tennessee State University
Graduate Degree/Institution: MS/George Washington University
Graduate program: Doctor of Public Health, Epidemiology
Year of Entry: Fall 2008
Research Advisor: Dr. Toni Bounds
Research Interests: Cancer
ClinicaL Trial Experiences
Protocol 2008XXXX: A Randomized Open-Label Study to Evaluate the Safety and Efficacy of XXXXX and Ibandronate in Postmenopausal Women Sub-Toptimally Treated with Daily or Weekly Biphospates.
Protocol 2008XXXX: A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Immune (Idiopathic). Thrombocytopenia Purpura (ITP)
Protocol 2007XXXX: A Phase 2 Randomized, Doublic-Blind, Placebo controlled, parallel group, fixed dose study of AMGXXX in subjects with chronic kidney disease on hemodialysis with hyperphospatemia
Protocol 2006XXXX: A Randomized, Double-Blind, Placeb0-Controlled, Multi-Center Phase 3 Study of XXXX, As Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-Care)
Protocol 2006XXXX: A Randomized, Double-Blind, Multi-Center Phase 2 Study, to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG XXX or Placebo in Subjects with Metastatic Clear Cell Carcinoma of the Kidney
Protocol 2006XXXX: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination with AMG XXX in Subjects with Advanced Recurrent Epithelial Ovarian or Paritoneal Cancer.
Protocol 2006XXXX: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of AMG XXX or Placebo in Combination with Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas.
Protocol 2006XXXX: Multi-Center, Open-Label, Randomized, Phas 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either XXXXXX or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer
Protocol 2006XXXX: Multi-center, Open-Label Single Arm Trial Evaluating XXXXXX in Combination with FOLFIRI Therapy Following First-line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer
Protocol 2006XXXX: Phase 2, Single Arm, Open-Label, Multi-Center Trial of Second-Line XXXXXX Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.
Protocol 2006XXXX: A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG XXX Treatment of Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
Protocol 2006XXXX: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Phase II Study to Determine the Safety and Efficacy of AMG XXX in Subjects with Moderate to Severe Asthma
Hypertension Regional Site Manager, Crowder Clinical Consulting, 2011-Present
Johnson City, TN Oncology Regional Site Manager, Amgen Inc., Thousand Oaks, California, 2005-2011
Clinical Research Associate, World Wide Clinical Trials, Atlanta, Georgia, 2000-2005
Clinical Research Associate, CTMS, Inc, Bristol, Tennessee, 1998-2000
QA Microbiologist, Laure Beverage Company, Johnson City, Tennessee, 1997-1998
Microbiology Laboratory Technician, Baxter Healthcare Corporation, Johnson City, Tennessee, 1994-1997
OSHA Hazardous Waste Operations and Emergency Response Certification, 2011
American Association of Clinical Research Professionals Certification, 2000